Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 3 |
List of Tables | 3 | 1 |
List of Figures | 4 | 1 |
Blueprint Medicines Corporation, Medical Equipment, Deals By Year, 2010 to YTD 2016 | 4 | 2 |
Blueprint Medicines Corporation, Medical Equipment Deals By Type, 2010 to YTD 2016 | 6 | 1 |
Blueprint Medicines Corporation, Medical Equipment, Deals By Region, 2010 to YTD 2016 | 7 | 1 |
Blueprint Medicines Corporation, Medical Equipment, Deals By Market, 2010 to YTD 2016 | 8 | 1 |
Blueprint Medicines Corporation, Medical Equipment, Deals Summary, 2010 to YTD 2016 | 9 | 1 |
Blueprint Medicines Corporation, Medical Equipment, Deal Details | 10 | 7 |
Venture Financing | 10 | 1 |
Blueprint Medicines Raises US$25 Million In Series B Venture Financing | 10 | 2 |
Blueprint Medicines Raises US$40 Million In Series A Venture Financing | 12 | 2 |
Partnerships | 14 | 1 |
Blueprint Medicines Enters into Co-Development Agreement with Ventana Medical Systems | 14 | 1 |
Personal Genome Diagnostics Enters Into Co-Development Agreement With Blueprint Medicines For Novel Kinase Targets | 15 | 1 |
Blueprint Medicines Enters Into Co-Development Agreement With Wellcome Trust Sanger Institute And Massachusetts General Hospital Cancer Center | 16 | 1 |
Blueprint Medicines Corporation - Key Competitors | 17 | 1 |
Key Employees | 18 | 1 |
Locations And Subsidiaries | 19 | 1 |
Head Office | 19 | 1 |
Recent Developments | 20 | 1 |
Financial Announcements | 20 | 1 |
Aug 09, 2016: Blueprint Medicines Reports Second Quarter 2016 Financial Results | 20 | 1 |
May 10, 2016: Blueprint Medicines Reports First Quarter 2016 Financial Results | 21 | 2 |
Mar 11, 2016: Blueprint Medicines Reports Fourth Quarter and Full Year 2015 Financial Results | 23 | 2 |
Corporate Communications | 25 | 1 |
Sep 06, 2016: Blueprint Medicines Announces Appointment of Tracey McCain as Chief Legal Officer and Executive Vice President | 25 | 1 |
Apr 15, 2016: Blueprint Medicines Appoints Lynn Seely, M.D. to Board of Directors | 26 | 1 |
Appendix | 27 | 1 |
Methodology | 27 | 1 |
About GlobalData | 27 | 1 |
Contact Us | 27 | 1 |
Disclaimer | 27 | 1 |